

Lipid lowering drugs:

It is important to note that no clinical trials have been used to evaluate these doses and their efficacies. The doses are gathered from multiple sources.

Fibrates (Gemfibrozil, Bezafibrate, Fenofibrate): decreases TG +/- CH

Gemfibrozil dose:

- **Dogs 200mg/day; 10mg/kg BID**
- **Cats 7.5-10mg/kg BID**

Bezafibrate dose: thought to be more efficacious than Gemfibrozil in humans and anecdotally in dogs; also anti-diabetic properties shown in humans), Not currently available in the US; can be obtained from Canada.

- **Dogs: 4-10mg/kg SID**

Fenofibrate: more effective than Gemfibrozil in humans

- **Dose extrapolated from Bezafibrate. Anecdotally, many start on the low end (4mg/kg SID) and work up.**

Side effects: none reported in animals for either medication. There was one recent study (2013) of Bezafibrate used in 46 dogs for both primary and secondary hyperlipidemia, and no adverse events were reported. In humans, there is a low incidence of myotoxicity and elevations of liver enzymes. Bezafibrate has less adverse effects in humans as compared to Gemfibrozil.